If you’re trying to manage risk in isolated silos, your quality management system is already obsolete.
What happens when a supplier changes a device label without triggering design controls? When operators quietly rework nonconforming product? Or when serious post-market signals never make it back into the risk file?
This Deep Dive examines recent FDA inspection and warning-letter examples through one common lens: the integration of risk management across the quality system.
The cases illustrate how seemingly separate failures in supplier controls, manufacturing, complaints, nonconforming product, CAPA, and infrastructure can become connected risk-management failures under QMSR.
Key highlights covered in the audio:
* Why ISO 13485 Clause 7.1 is becoming so important — and how risk management increasingly connects multiple parts of the QMS.
* Supplier changes can become risk-management events when labeling, intended use, or other product assumptions change without adequate escalation.
* Undocumented shop-floor rework can hide risk signals, leaving management metrics looking healthy while process problems accumulate.
* CAPA cannot work in isolation when environmental controls, process data, nonconformances, and risk analyses are disconnected.
* A static risk file is no longer enough. Post-market experience, manufacturing changes, supplier issues, and emerging hazards must continually inform lifecycle risk management.
The broader lesson is straightforward: QMSR is pushing companies away from managing compliance clause by clause and toward managing risk as an interconnected system.
And that raises an important question for medical device organizations:
When a new signal appears anywhere in your quality system, can it actually find its way back to the assumptions in your risk analysis?
Keywords:
QMSR, ISO 13485, ISO 14971, Risk Management, FDA Warning Letters, CAPA, Supplier Controls, Nonconforming Product, Design Changes, Lifecycle Risk Management
🎧 Listen to the Deep Dive for a closer look at what recent FDA QMSR warning letters reveal about the growing expectation to integrate risk management across the entire quality system.
Thanks for reading Let's Talk Risk!. If you liked this post, share with others.
Note:
The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis:
* FDA (2026). Warning Letter to Koven Technologies, Inc. (MARCS-CMS 734643).
* FDA (2026). Warning Letter to Linemaster Switch Corporation (MARCS-CMS 730215).
* FDA (2026). Warning Letter to Nipro Renal Solutions USA, Corporation (MARCS-CMS 732874).
* FDA (2026). Medical Device Inspection Citations Data (2025–2026 Log), Regulatory Inspection Dataset (Form FDA 483 Observations).
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe
